HPV Vaccine Drops Cervical Cancer Deaths to Nearly Zero

For the first time in history, doctors are seeing an entire generation of young women virtually protected from a deadly cancer.

A groundbreaking study from Queen Mary University of London analyzed national health records in England and found something remarkable. Girls who received the HPV vaccine at age 12 to 13 now have close to zero risk of dying from cervical cancer before age 30.

The numbers tell an incredible story. Between 2000 and 2024, for the first time ever over a five-year period, there were zero recorded cervical cancer deaths among women between ages 20 and 24 in England. Without vaccination, researchers expected around 23 deaths in that age group.

Since England started offering the vaccine to school-age girls in 2008, the program has saved approximately 200 lives. The study, published in The Lancet medical journal, represents the first comprehensive analysis of its kind showing real-world prevention of cancer deaths.

The HPV vaccine works by protecting against multiple strains of human papillomavirus, which causes cervical cancer and other cancers. When the vaccine launched in the United States in 2006, it protected against four strains. By 2014, it expanded to cover nine strains that account for roughly 90 percent of HPV-related cancers worldwide.

Dr. Megan Yanny, a pediatrician at University of Wisconsin Health Kids, calls it a historic breakthrough. The incidence of HPV lesions and precancerous cervical lesions in young American women has decreased by nearly 80 percent since 2008.

The Ripple Effect

This success story extends beyond England. Australia and the United Kingdom have both seen dramatic results from their HPV vaccination programs, proving the vaccine works across different populations and healthcare systems.

The vaccine represents something people have longed for: real cancer prevention. While approximately one in three Americans will be diagnosed with cancer in their lifetime, the HPV vaccine offers proven protection against multiple cancer types before they can even develop.

Medical professionals across the United States are celebrating the 20th anniversary of the vaccine's FDA approval as a landmark achievement in women's health and public health. The vaccine doesn't just treat cancer or catch it early. It stops cancer from forming in the first place.

The United States has set a goal of vaccinating 80 percent of adolescents against HPV by 2030. Research shows that effective messaging about the vaccine should focus on its proven ability to prevent cancer rather than dwelling on how the virus spreads.

When talking with friends and family about the HPV vaccine, the evidence speaks clearly: this is a vaccine that saves lives by preventing cancer, and we're now watching an entire generation reap those benefits.